Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
Meet the Executive: Tal Heppenstall, President of UPMC Enterprises
It’s been five years since UPMC rebranded its long-standing work on health care innovation and …
Read More →
RxAnte launches technology-enabled comprehensive pharmacy service for medically complex and vulnerable Medicare members
RxAnte, a UPMC Enterprises portfolio company, recently developed and launched a transformative direct-to-member service that …
Read More →